| Name | Title | Contact Details |
|---|---|---|
Dan Eastman |
Chief Information Officer | Profile |
Klearview Manor Nursing Home is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Klearview Manor Nursing Home is based in Fairfield, ME. You can find more information on Klearview Manor Nursing Home at www.northcountryassociates.com
Riverside Physician Service is a Bradenton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In January 2014, Jordan Hospital joined the Beth Israel Deaconess Medical Center family of hospitals and become Beth Israel Deaconess Hospital-Plymouth. In 1899, a group of leading citizens from Plymouth saw a need to build a hospital to serve residents and pursued the idea of "a hospital on the hill". They approached retail tycon, philanthropist, and summer resident Eben Jordan, of the Jordan Marsh Company, and he donated $20,000 to build was was to become Jordan Hospital. In December 1903, Jordan Hospital opened its doors to the first patients and has remained a community hospital ever since. In 2014, Jordan Hospital become Beth Israel Deaconess Hospital-Plymouth and remains a private, not-for-profit hospital. We treat all patients, regardless of ability to pay. We proudly serve the communities of Bourne, Carver, Duxbury, Halifax, Kingston, Lakeville, Pembroke, Plympton, Plymouth, Marshfield, Middleboro, Sandwich and Wareham, as well as numerous visitors to our historic area. Beth Israel Deaconess-Plymouth is an affiliate of Beth Israel Deaconess Medical Center in Boston.
River Edge Behavioral Health Center has been providing mental health, mental retardation and substance abuse services to the citizens of Middle Georgia since 1994. River Edge strives to be the leader in behavioral healthcare providing comprehensive
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.